ECDC poster at the 16th European AIDS Conference, 2017, Milan.
Authors: Lara Tavoschi, Joana Gomes-Dias, Anastasia Pharris, the EU/EEA HIV Surveillance Network
Presentation by ECDC HIV expert Anastasia Pharris on epidemiological challenges for the HIV response in Europe.
Presented at: 16th European AIDS Conference, 26 October 2017, Milan.
Presentation during the 17th European AIDS Conference (EACS) 2019 looking at the status of HIV pre-exposure prophylaxis PrEP in Europe..
Presenter: Teymur Noori, European Centre for Disease Prevention and Control (ECDC)
Although HIV is preventable through effective public health measures, significant HIV transmission continues in Europe. In 2015, almost 30 000 people were diagnosed in European Union and European Economic Area Member States; a rate of 6.3 cases in every 100 000 people (when adjusted for reporting delay).
This report, prepared jointly with the WHO Regional Office for Europe, presents data on HIV and AIDS for the whole European Region, including the EU and EEA countries. Analyses are provided for the EU and EEA region.
Data and trends on hepatitis B and C for the countries of the European Union and European Economic Area.
2015 data.
See also ECDC's Annual Epidemiological Report: https://ecdc.europa.eu/en/annual-epidemiological-reports
Presentation on epi data during the conference "New challenges and unmet needs of children and adolescents living and ageing with HIV/AIDS", 19-22 January 2017, Bucharest, Romania
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: ECDC's HIV expert Anastasia Pharris
a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Presentation by ECDC HIV expert Anastasia Pharris on epidemiological challenges for the HIV response in Europe.
Presented at: 16th European AIDS Conference, 26 October 2017, Milan.
Presentation during the 17th European AIDS Conference (EACS) 2019 looking at the status of HIV pre-exposure prophylaxis PrEP in Europe..
Presenter: Teymur Noori, European Centre for Disease Prevention and Control (ECDC)
Although HIV is preventable through effective public health measures, significant HIV transmission continues in Europe. In 2015, almost 30 000 people were diagnosed in European Union and European Economic Area Member States; a rate of 6.3 cases in every 100 000 people (when adjusted for reporting delay).
This report, prepared jointly with the WHO Regional Office for Europe, presents data on HIV and AIDS for the whole European Region, including the EU and EEA countries. Analyses are provided for the EU and EEA region.
Data and trends on hepatitis B and C for the countries of the European Union and European Economic Area.
2015 data.
See also ECDC's Annual Epidemiological Report: https://ecdc.europa.eu/en/annual-epidemiological-reports
Presentation on epi data during the conference "New challenges and unmet needs of children and adolescents living and ageing with HIV/AIDS", 19-22 January 2017, Bucharest, Romania
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: ECDC's HIV expert Anastasia Pharris
a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
ECDC presentation at the 15th Conference of the International Society of Travel Medicine, 15 May 2017.
Presenter: Teymur Noori
Questions?
Contact info@ecdc.europa.eu
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation: ECDC Acting Director Dr Andrea Ammon.
a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Although HIV is preventable through effective public health measures, significant HIV transmission continues in Europe. In 2014, almost 30 000 people were diagnosed in European Union and European Economic Area Member States. This slide set includes maps, graphs and tables from the 2014 HIV/AIDS surveillance report, published jointly by ECDC and WHO Europe.
Presentation from the opening session of the 17th European AIDS Conference (EACS) 2019, Basel, Switzerland.
Presenter: Anastasia Pharris, European Centre for Disease Prevention and Control.
ECDC symposium "Responding to two of the main STI threats of our time: syphilis and antimicrobial resistant Neisseria gonorrhoeae"
Presentation by: Otilia Mårdh
Presented at: IUSTI 2019, Tallinn
Summary slides on the epidemiological situation in the EU/EEA.
2018 surveillance data.
Report and ppt slides available from: http://bit.ly/HIVAIDSsurv18
Hepatitis E is one of the most common causes of acute hepatitis in the EU/EEA but currently not notifiable at EU level.
This presentation summarises ECDC's work on the topic and survey results on hepatitis E on 2005 to 2015 data.
Any questions? Contact press@ecdc.europa.eu
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Teymur Noori, ECDC
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Presentation at European Harm Reduction Conference
Bucharest, 21 November 2018
Author Anastasia Pharris, European Centre for Disease Prevention and Control (ECDC)
Shigellosis outbreaks associated with sexual transmission among men who have sex with men (MSM) have been reported in recent years from the United Kingdom, Germany and Spain, with severe infections among HIV-positive MSM.
Poster at ESCAIDE conference 2016, Stockholm.
During the first 2 months of 2017 we have seen 1524 cases of measles reported from 14 EU/EEA countries. Measles does not only affect children but also older age groups. In 2014 over half of the cases were in adults over 20 years old, in 2015 and 2016 this age group accounted for approximately one third of all cases. Closing immunisation gaps in adolescents and adults who have not received vaccination in the past as well as strengthening routine childhood immunisation programmes will be vital to prevent future outbreaks and reach the elimination goal.
Presentation during the EU session "Eliminationm of hepatitis B and C in teh EU: challenges and opportunities", at the International Liver Congress (ILC) 2017 in Amsterdam.
Presenter: Erika Duffell, European Centre for Disease Prevention and Control (ECDC)
Data and trends from the ECDC Annual Epidemiological reports for 2016 on:
Chlamydia (http://bit.ly/AERch16)
Lymphogranuloma venereum (http://bit.ly/AERLGV16)
Gonorrhoea (http://bit.ly/AERsy16)
Syphilis (http://bit.ly/AERsy16)
Congenital syphilis (http://bit.ly/AERcs16)
See also: https://ecdc.europa.eu/en/annual-epidemiological-reports
This presentation summarises the main data from the ECDC Annual epidemiological reports 2017 on chlamydia, gonorrhoea, lymphogranuloma venereum, (congenital) syphilis
There is a growing body of evidence indicating an increased burden of HIV among older adults. We describe the socio-demographic profile of adults aged 50 years and
over that are newly diagnosed with HIV in the European Union/European Economic Area (EU/EEA), to inform HIV testing and prevention efforts.
Poster at EACS 2015.
Poster presentation at the AIDS 2018 conference in Amsterdam.
By: Marieke J. van der Werf and Csaba Ködmön, European Centre for Disease Prevention and Control, ECDC.
ECDC presentation at the 15th Conference of the International Society of Travel Medicine, 15 May 2017.
Presenter: Teymur Noori
Questions?
Contact info@ecdc.europa.eu
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation: ECDC Acting Director Dr Andrea Ammon.
a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Although HIV is preventable through effective public health measures, significant HIV transmission continues in Europe. In 2014, almost 30 000 people were diagnosed in European Union and European Economic Area Member States. This slide set includes maps, graphs and tables from the 2014 HIV/AIDS surveillance report, published jointly by ECDC and WHO Europe.
Presentation from the opening session of the 17th European AIDS Conference (EACS) 2019, Basel, Switzerland.
Presenter: Anastasia Pharris, European Centre for Disease Prevention and Control.
ECDC symposium "Responding to two of the main STI threats of our time: syphilis and antimicrobial resistant Neisseria gonorrhoeae"
Presentation by: Otilia Mårdh
Presented at: IUSTI 2019, Tallinn
Summary slides on the epidemiological situation in the EU/EEA.
2018 surveillance data.
Report and ppt slides available from: http://bit.ly/HIVAIDSsurv18
Hepatitis E is one of the most common causes of acute hepatitis in the EU/EEA but currently not notifiable at EU level.
This presentation summarises ECDC's work on the topic and survey results on hepatitis E on 2005 to 2015 data.
Any questions? Contact press@ecdc.europa.eu
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Teymur Noori, ECDC
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Presentation at European Harm Reduction Conference
Bucharest, 21 November 2018
Author Anastasia Pharris, European Centre for Disease Prevention and Control (ECDC)
Shigellosis outbreaks associated with sexual transmission among men who have sex with men (MSM) have been reported in recent years from the United Kingdom, Germany and Spain, with severe infections among HIV-positive MSM.
Poster at ESCAIDE conference 2016, Stockholm.
During the first 2 months of 2017 we have seen 1524 cases of measles reported from 14 EU/EEA countries. Measles does not only affect children but also older age groups. In 2014 over half of the cases were in adults over 20 years old, in 2015 and 2016 this age group accounted for approximately one third of all cases. Closing immunisation gaps in adolescents and adults who have not received vaccination in the past as well as strengthening routine childhood immunisation programmes will be vital to prevent future outbreaks and reach the elimination goal.
Presentation during the EU session "Eliminationm of hepatitis B and C in teh EU: challenges and opportunities", at the International Liver Congress (ILC) 2017 in Amsterdam.
Presenter: Erika Duffell, European Centre for Disease Prevention and Control (ECDC)
Data and trends from the ECDC Annual Epidemiological reports for 2016 on:
Chlamydia (http://bit.ly/AERch16)
Lymphogranuloma venereum (http://bit.ly/AERLGV16)
Gonorrhoea (http://bit.ly/AERsy16)
Syphilis (http://bit.ly/AERsy16)
Congenital syphilis (http://bit.ly/AERcs16)
See also: https://ecdc.europa.eu/en/annual-epidemiological-reports
This presentation summarises the main data from the ECDC Annual epidemiological reports 2017 on chlamydia, gonorrhoea, lymphogranuloma venereum, (congenital) syphilis
There is a growing body of evidence indicating an increased burden of HIV among older adults. We describe the socio-demographic profile of adults aged 50 years and
over that are newly diagnosed with HIV in the European Union/European Economic Area (EU/EEA), to inform HIV testing and prevention efforts.
Poster at EACS 2015.
Poster presentation at the AIDS 2018 conference in Amsterdam.
By: Marieke J. van der Werf and Csaba Ködmön, European Centre for Disease Prevention and Control, ECDC.
Good surveillance is at the heart of the fight against Hepatitis C however continued lack of epidemiological data remains a problem.
Although progress has been made to improve education and increase outreach programmes, the prevalence of free testing and lack of specific awareness campaigns is impeding progress in the move towards evidence-based policy.
Tackling hepatitis C: Moving towards an integrated policy approach is an Economist Intelligence Unit report, supported by Janssen, which investigates national and multinational policy initiatives to combat the hepatitis C virus.
Read more>> bit.ly/HCpFB1
Clinical Epidemiological Study of Secondary Syphilis - Current Scenarioiosrjce
IOSR Journal of Dental and Medical Sciences is one of the speciality Journal in Dental Science and Medical Science published by International Organization of Scientific Research (IOSR). The Journal publishes papers of the highest scientific merit and widest possible scope work in all areas related to medical and dental science. The Journal welcome review articles, leading medical and clinical research articles, technical notes, case reports and others.
People Living with Human Immunodeficiency Virus in Hadhramout: Clinical Prese...asclepiuspdfs
The objective of the study was to determine the clinical features and outcome of patients living with human immunodeficiency virus (HIV) in Hadhramout and nearby governorates. Materials and Methods: This descriptive study was conducted in the antiretroviral therapy (ART) site at Ibn-Sina General Hospital, Mukalla, Hadhramout governorate. All 145 patients were enrolled in HIV treatment and care program from December 2008 to the end of December 2016 with confirmed HIV test. Data included all personal data, clinical staging, drugs taken, and outcomes. Patients were grouped according to the decades to five groups, ≤15 years, 16–30 years, 31–50 years, 51–70 years, and >70 years. Cases classify according to the antiretroviral drugs to ART group and Pre-ART group. The relevant data parameters were analyzed using SPSS statistical software version 21 and Excel 10. Results: A total of 145 cases, most adults (97.9%), males and females were104 (71.7%) and 41 (28.3%), respectively. Mean age was 36.46 years and 30–50 years the most affected age group (55.2%). Clinical Stages 3 and 4 were the common presentation in 73.8%, and most cases were from Mukalla city. Of the total cases, 74.5% were on ART 53.1 of them improved, pulmonary tuberculosis was found in 4 cases, and death cases were (18.5%), mostly due to late presentation and non-adherence, and mostly occurred in early 6 months of starting the ART. 37 patients were in a pre-treatment group (21.6%), where the mortality rate is 35.1%, mainly due to loss of follow-up. Conclusions: Most cases were adult males, young age and have had late presentation, where mortality is higher in the pre-treatment group due to loss of follow-up and in early 6 months of treatment.
Impact of pulmonary tuberculosis in hiv patients, retrospective study from ja...Dr Nzasi Deppinair Mundabi
A research done by Dr Mundabi to find out how the impact of TB to HIV patients especially concerning the CD4 for patients on ART and regularly followed up.
Public Health - Incidence Prevalence Prevention of HIV in the UK - government situation report 2015 - improving the nations health - Impact on budget nhs england - care quality commission - health tourism - migrant burden - healthcare - hospitals treating disease.
This is technical writing Assignment, no emotions go straight to t.docxchristalgrieg
This is technical writing Assignment, no emotions go straight to the point.
Section 1: Introduction
The rise in the numbers of Human Immunodeficiency Virus (HIV) diagnoses is notable especially for racial and ethnic minority youth and adolescents aged 13 to 19 years (National Institute of Health, 2013). Approximately one half of all new HIV infections in the United States occur among person(s) younger than 25 years. Nearly 4 million new sexually transmitted infection (STI) cases each year occur among youth and adolescents (NIH, 2013). Reconciling data of 2015, 54.2% of high school students reported having sexual intercourse; of students reported sex during the previous months, 39% stated they didn’t use a condom during their last sexual encounter (United States Census Bureau, 2014). The number of sexually active among youth and adolescents, from 2001 to 2014, there’s been a significant increase in the percentage of youth and adolescents who were never taught about HIV/AIDS. Unified national HIV/AIDS surveillance system has enhanced the ability to monitor and characterize racial and ethnic minority youth populations affected by the HIV epidemic and provide information on the entire population of HIV infected persons who have been tested confidentially (NIH, 2014). Approximately 1.2 million people were living with HIV in the United States in 2014, 49% and 51% undiagnosed infections. Almost 50,000 people become newly infected each year, and in 2014, the estimated rate of diagnoses of HIV infection was 13.8 per 100,000 population (National Institute of Health, 2014). Social trust is associated with lowering the of course mortality rates and that associated HIV infection varied within racial and ethnic minority youth and adolescents. The risk factors that will be addressed in this paper are unprotected vaginal or anal sex, improving access to prevention and care services, inadequate sex education and drug use
Unprotected vaginal and anal sex
Participating in unprotected vaginal and anal sex, or sex without latex or polyurethane condoms is a major contributing factor of HIV rate in racial and ethnic minority youth and adolescents. In an infected youth or adolescents, the semen and blood contains high amount of HIV. During unprotected vaginal and anal sex HIV can easily pass from one person to another. Several studies link alcohol and drug use to higher rates of unprotected anal intercourse, higher numbers of sex partners, and inconsistent condom use (NIH, 2014). With these trends among racial and ethnic minority National HIV Behavioral Surveillance (2015) reported 21% minority youth and adolescent are infected with HIV while 79% youth and adolescent don’t know their status (National HIV Behavioral Surveillance, 2015).
Improving access to prevention and care services
Access to HIV prevention and treatment is an important step in helping achieve an HIV free generation, especially among racial and ethnic minority youth and adolescent. If someone ...
GENDER DIFFERENCE ON CASE DETECTION OF PULMONARY - Dr. Kapil Amgain DrKapilAmgain
GENDER DIFFERENCE ON CASE DETECTION OF PULMONARY
TUBERCULOSIS AMONG THE SUSPECTED CASES ATTENDING
IN JUTPANI PRIMARY HEALTH CENTRE OF CHITWAN, NEPAL.
Amgain Kapil1, Paudel DP2, Paneru DP3, Dhital Mukesh4, Amgain Ganesh5
1 Tribhuvan University, Central Department of Zoology, University Campus, Kirtipur, Kathmandu, Nepal
2 Department of Public Health, JN Medical College, KLE University, Nehru Nagar, Belgaum, Karnataka, India
3 Department of Public Health, Pokhara University, Kaski, Nepal
4 JN Medical College, KLE University, Nehru Nagar, Belgaum, Karnataka, India
5 Tribhuvan University, Central Department of Phychology, University Campus, Kirtipur, Kathmandu, Nepal
Providing an overview on data, trends and summary of findings on the hepatitis B and C surveillance data from EU/EEA countries for the year 2017:
Find ECDC's Annual Epidemiological reports online: http://bit.ly/ECDCAER
HIV transmission remains a major public health concern and affects more than 2 million people in the WHO European Region.
These ECDC slides summarise findings from the report which is available via http://bit.ly/WAD_18
What is the current situation of HIV in Europe and Central Asia?
How can we more effectively prevent new infections?
Presentation by Anastasia Pharris,
European Centre for Disease Prevention and Control (ECDC)
at Glasgow HIV Drug Therapy Conference
28 October 2018
Teymur Noori, ECDC
22nd International AIDS Conference, Amsterdam 2018
2018 European African HIV/AIDS & Hepatitis C Community Summit. "Our Voices Matter for a lasting solution!!"
Poster presentation at the AIDS 2018 conference in Amsterdam.
By: Adam Bourne1, Beatrice Alba1, Alex Garner2, Gianfranco Spiteri3, Anastasia Pharris3, Teymur Noori3
1. Australian Research Centre in Sex, Health & Society, La Trobe University, Melbourne, Australia; 2. Hornet Gay Social Network, California, USA; 3. European Centre for Disease Prevention and Control, ECDC, Sweden
Presentation by Daniel Simões, HIV in Europe, Portugal , at AIDS 2018 conference during the joint ECDC and EACS satellite "Getting to 90: Addressing inequalities in the HIV continuum of care in Europe and Central Asia"
Presentation by Jens Lundgren, Rigshospitalet, University of Copenhagen - European AIDS Clinical Society, Denmark, at AIDS 2018 conference during the joint ECDC and EACS satellite "Getting to 90: Addressing inequalities in the HIV continuum of care in Europe and Central Asia"
Presentation by Chloe Orkin, Royal London Hospital - BHIVA, United Kingdom, at AIDS 2018 conference during the joint ECDC and EACS satellite "Getting to 90: Addressing inequalities in the HIV continuum of care in Europe and Central Asia"
Presentation by Teymur Noori, ECDC, at AIDS 2018 conference during teh joint ECDC and EACS satellite "Getting to 90: Addressing inequalities in the HIV continuum of care in Europe and Central Asia"
Summary of surveillance data for hepatitis B and hepatitis C across the European Union and European Economic area for 2016.
See also:
ECDC's Annual Epidemiological Report hepatitis B: http://bit.ly/AER16HBV
ECDC's Annual Epidemiological Report hepatitis C: http://bit.ly/AER16HCV
Presentation by: Erika Duffell, European Centre for Disease Prevention and Control, Stockholm, Sweden
Presentad at: International Liver Congress, April 2018
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
ABDOMINAL TRAUMA in pediatrics part one.drhasanrajab
Abdominal trauma in pediatrics refers to injuries or damage to the abdominal organs in children. It can occur due to various causes such as falls, motor vehicle accidents, sports-related injuries, and physical abuse. Children are more vulnerable to abdominal trauma due to their unique anatomical and physiological characteristics. Signs and symptoms include abdominal pain, tenderness, distension, vomiting, and signs of shock. Diagnosis involves physical examination, imaging studies, and laboratory tests. Management depends on the severity and may involve conservative treatment or surgical intervention. Prevention is crucial in reducing the incidence of abdominal trauma in children.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
New HIV diagnoses among older adults in the EU/EEA: Missed opportunities and barriers to testing
1. PE23/46 - Increasing Trend of New HIV Diagnoses among
Older Adults in the EU/EEA: Missed Opportunities and
Barriers to Testing
Lara Tavoschi1, Joana Gomes-Dias1, Anastasia Pharris1, the EU/EEA HIV Surveillance Network
1 European Centre for Disease Prevention and Control, ECDC, Sweden
Background
There is accumulating evidence that indicates an increased burden of
HIV among older adults. HIV prevalence has risen in this age group
following better access to effective antiretroviral treatment (ART)
which allows longer and healthier lives. In addition, there are reports
of increasing trends in new HIV diagnoses among older adults in some
high income countries. Here we describe factors associated with HIV
infection and diagnosis among older adults in the EU/EEA to support
policy decisions as well as the design of effective interventions
focussing on this age group. To this end, we analysed new HIV
diagnoses reported by EU/EEA countries during the period 2004-2015
Methods
We defined older and younger adults as ≥50 and 15-49 years old,
respectively. We extracted new HIV diagnoses reported to the
European Surveillance System during 2004-2015 and stratified them
by age, gender, migration status, transmission route and CD4 count.
We performed comparisons between the two age groups using chi-
square test for difference, and assessed temporal trends using linear
regression analysis.
Results
17.3% (5076/29419) of new HIV diagnoses reported in 2015 were
among older adults. Overall the rate of new HIV diagnoses among
older adults was 2.5 per 100 000 population, ranging between 0.4
(Slovakia) and 7.5 (Estonia) per 100 000 population (Figure 1).
In 2015, the gender-specific rates of new diagnoses were 1.05 per
100 000 older females and 4.3 per 100 000 older males.
Reported transmission routes showed a pattern significantly
associated with age (p<0.0001), with a higher proportion of cases
attributed to heterosexual transmission among older adults as
compared to younger adults (Table 1).
A significantly higher proportion of older adults were diagnosed late
(p<0.0001). This is also reflected in the significantly lower median
CD4 count at diagnosis among older adults older adults as compared
to younger adults (Table 1).
In the period 2004-2015, a total of 54102 cases were reported
among older adults corresponding to an average rate of 2.6 per 100
000 population, significantly increasing (annual average change 2.1;
95%CI 1.1%-3.1%; p=0.0009) over the 12-year period.
At national level, we observed significant increase in rates of new HIV
diagnosis among older adults in 16 countries, and a significant
decrease in one. In younger adults, we observed significant increases
in 12 countries and a significant decrease in six(Figure 2).
Conclusions
There is an increasing trend in new HIV diagnoses being reported
among older adults in the EU/EEA. Distinctive features characterise
this population sub-group, such as being diagnosed late,
predominantly originating from the country in which they are
diagnosed, and reporting heterosexual transmission of HIV.
The increasing trend in new HIV diagnoses coupled with the large
proportion of older adults being diagnosed late point towards the
compelling need to heighten awareness among health care
providers and deliver more targeted prevention interventions.
Our results indicate the coverage and uptake of HIV testing needs
to be scaled up significantly, and not only among older adults but
among the adult population at large. Based on the current
evidence, this could be effectively achieved in the EU/EEA through
the wider implementation of promising approaches such as
provider-initiated and indicator-condition guided testing programs.
Table 1: Characteristics of new HIV diagnoses among persons 15-49 years
and persons 50 years and older, EU/EEA countries, 2015 (n=29 419)
Figure 2: Average annual percentage change of trend in new HIV diagnoses
in people aged 50 years and over by country, EU/EEA, 2004-2015
Acknowledgements
Andrew Amato Gauci, Judit Takacs (ECDC), and ECDC library
Figure 1: New HIV diagnoses among adults aged 50 years and over per 100
000 persons in the same age category, by country, EU/EEA, 2015
Tavoschi L, Gomes Dias J, Pharris A; EU/EEA HIV Surveillance Network. New HIV diagnoses among adults aged 50 years or older in 31
European countries, 2004-15: an analysis of surveillance data. Lancet HIV. 2017 Sep 26. pii: S2352-3018(17)30155-8. doi: 10.1016/S2352-
3018(17)30155-8